- Home
- VACH vs AVIR Comparison
VACH vs AVIR Comparison
Compare VACH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VACH
- AVIR
- Stock Information
- Founded
- VACH 2023
- AVIR 2012
- Country
- VACH United States
- AVIR United States
- Employees
- VACH N/A
- AVIR N/A
- Industry
- VACH
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- VACH
- AVIR Health Care
- Exchange
- VACH NYSE
- AVIR Nasdaq
- Market Cap
- VACH 324.2M
- AVIR 273.7M
- IPO Year
- VACH 2024
- AVIR 2020
- Fundamental
- Price
- VACH $10.29
- AVIR $2.63
- Analyst Decision
- VACH
- AVIR Hold
- Analyst Count
- VACH 0
- AVIR 1
- Target Price
- VACH N/A
- AVIR $6.00
- AVG Volume (30 Days)
- VACH 175.9K
- AVIR 525.1K
- Earning Date
- VACH 01-01-0001
- AVIR 05-12-2025
- Dividend Yield
- VACH N/A
- AVIR N/A
- EPS Growth
- VACH N/A
- AVIR N/A
- EPS
- VACH 0.26
- AVIR N/A
- Revenue
- VACH N/A
- AVIR N/A
- Revenue This Year
- VACH N/A
- AVIR N/A
- Revenue Next Year
- VACH N/A
- AVIR N/A
- P/E Ratio
- VACH $40.12
- AVIR N/A
- Revenue Growth
- VACH N/A
- AVIR N/A
- 52 Week Low
- VACH $9.95
- AVIR $2.60
- 52 Week High
- VACH $11.20
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- VACH N/A
- AVIR 39.68
- Support Level
- VACH N/A
- AVIR $2.66
- Resistance Level
- VACH N/A
- AVIR $3.01
- Average True Range (ATR)
- VACH 0.00
- AVIR 0.15
- MACD
- VACH 0.00
- AVIR -0.02
- Stochastic Oscillator
- VACH 0.00
- AVIR 2.17
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).